

### Company Overview

CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing.

Our revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics.

Our mission at CollPlant is to deliver ground-breaking products for regenerative medicine that offer the optimal treatment options to patients.

### CollPlant To Present at the H.C. Wainwright Global Life Sciences Conference

Mar 4 2021, 7:00 AM EST

### Termination of Licensing Agreement for Bioprinting of Scaffolds for Lung Transplants

Feb 25 2021, 9:20 AM EST

### CollPlant Issues Letter to Shareholders

Feb 18 2021, 9:31 AM EST

### Stock Overview

Symbol	CLGN	Eran Rotem
Exchange	Nasdaq	Deputy CEO & CFO
Market Cap	114.16m	T: +972 (73) 2325612
Last Price	\$12.29	F: +972 (73) 2325602
52-Week Range	\$6.00 - \$24.27	<a href="mailto:eran@collplant.com">eran@collplant.com</a>

03/04/2021 04:00 PM EST

### Investor Relations

### Management Team

#### Yehiel Tal

Chief Executive Officer

#### Prof. Oded Shoseyov

Founder, Chief Scientist

#### Eran Rotem, CPA

Deputy CEO and Chief Financial Officer

#### Dr. Nadav Orr

Vice President, Research and Development

#### Dr. Ilana Belzer

Chief Operating Officer

#### Dr. Philippe Bensimon

Vice President, Regulatory Affairs and Quality Assurance

### CollPlant Biotechnologies Ltd.

4 Oppenheimer St.,  
P.O.B 4132  
Rehovot 7670104,  
Israel

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.